Literature DB >> 19336572

Noninvasive detection of lentiviral-mediated choline kinase targeting in a human breast cancer xenograft.

Balaji Krishnamachary1, Kristine Glunde, Flonne Wildes, Noriko Mori, Tomoyo Takagi, Venu Raman, Zaver M Bhujwalla.   

Abstract

Elevated phosphocholine (PC) and total choline (tCho) metabolites are widely established characteristics of most cancer cells, including breast cancer. Effective silencing of choline kinase (chk), the enzyme that converts choline to PC, is associated with reduced tumor growth. The functional importance and down-regulation of chk using RNA interference has been previously established. Here, we report on the preclinical evaluation of lentiviral vector-mediated down-regulation of chk using short hairpin RNA (shRNA) in established tumors derived from human breast cancer cells. Concentrated lentivirus expressing shRNA against chk was injected i.v. in the tail vein of MDA-MB-231 tumor-bearing female severe combined immunodeficient mice. Transduction efficiency in cells and tumors in vivo was assessed optically by enhanced green fluorescent protein expression and additionally from chk mRNA and protein levels. An 80% reduction in chk mRNA and protein was achieved following approximately 90% transduction efficiency in cells. After transduction with chk-shRNA, (1)H magnetic resonance spectroscopy (MRS) of cell and tumor extracts showed decreases in PC and tCho levels (P < 0.01 and 0.05, respectively) in comparison with controls. PC levels were monitored noninvasively by (31)P MRS in tumors and by (1)H MRS in cell and tumor tissue extracts. Noninvasive (31)P MR spectra of chk-shRNA-transduced tumors in vivo showed lower PC and phosphomonoester levels that were associated with reduced tumor growth and proliferation. This study shows the use of lentiviral vectors to target chk in a human breast cancer xenograft and noninvasive MRS detection of this targeting.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19336572      PMCID: PMC2687146          DOI: 10.1158/0008-5472.CAN-08-4120

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  24 in total

1.  A new rapid immunohistochemical staining technique using the EnVision antibody complex.

Authors:  U Kämmerer; M Kapp; A M Gassel; T Richter; C Tank; J Dietl; P Ruck
Journal:  J Histochem Cytochem       Date:  2001-05       Impact factor: 2.479

Review 2.  Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy.

Authors:  E Vigna; L Naldini
Journal:  J Gene Med       Date:  2000 Sep-Oct       Impact factor: 4.565

3.  Biodistribution and toxicity studies of VSVG-pseudotyped lentiviral vector after intravenous administration in mice with the observation of in vivo transduction of bone marrow.

Authors:  Dao Pan; Roland Gunther; Weiming Duan; Steve Wendell; William Kaemmerer; Tal Kafri; Inder M Verma; Chester B Whitley
Journal:  Mol Ther       Date:  2002-07       Impact factor: 11.454

4.  Real-time changes in 1H and 31P NMR spectra of malignant human mammary epithelial cells during treatment with the anti-inflammatory agent indomethacin.

Authors:  Kristine Glunde; Ellen Ackerstaff; Kshama Natarajan; Dmitri Artemov; Zaver M Bhujwalla
Journal:  Magn Reson Med       Date:  2002-11       Impact factor: 4.668

5.  Sustainable systemic delivery via a single injection of lentivirus into human skin tissue.

Authors:  S C Baek; Q Lin; P B Robbins; H Fan; P A Khavari
Journal:  Hum Gene Ther       Date:  2001-08-10       Impact factor: 5.695

6.  Reduction of vascular and permeable regions in solid tumors detected by macromolecular contrast magnetic resonance imaging after treatment with antiangiogenic agent TNP-470.

Authors:  Zaver M Bhujwalla; Dmitri Artemov; Kshama Natarajan; Meiyappan Solaiyappan; Peggy Kollars; Paul E G Kristjansen
Journal:  Clin Cancer Res       Date:  2003-01       Impact factor: 12.531

7.  Regression of prostate cancer xenografts by a lentiviral vector specifically expressing diphtheria toxin A.

Authors:  Jun-ying Zheng; Danlin Chen; Justin Chan; Duan Yu; Eugene Ko; Shen Pang
Journal:  Cancer Gene Ther       Date:  2003-10       Impact factor: 5.987

8.  Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy.

Authors:  Ana Ramírez de Molina; Ruth Gutiérrez; Maria Angeles Ramos; José María Silva; Javier Silva; Félix Bonilla; José Javier Sánchez; Juan Carlos Lacal
Journal:  Oncogene       Date:  2002-06-20       Impact factor: 9.867

Review 9.  Choline phospholipid metabolism: a target in cancer cells?

Authors:  Ellen Ackerstaff; Kristine Glunde; Zaver M Bhujwalla
Journal:  J Cell Biochem       Date:  2003-10-15       Impact factor: 4.429

10.  Efficient lentiviral vectors for short hairpin RNA delivery into human cells.

Authors:  Dong Sung An; Yiming Xie; Si Hua Mao; Kouki Morizono; Sam K P Kung; Irvin S Y Chen
Journal:  Hum Gene Ther       Date:  2003-08-10       Impact factor: 5.695

View more
  40 in total

1.  Metabolic signatures imaged in cancer-induced cachexia.

Authors:  Marie-France Penet; Mayur M Gadiya; Balaji Krishnamachary; Sridhar Nimmagadda; Martin G Pomper; Dmitri Artemov; Zaver M Bhujwalla
Journal:  Cancer Res       Date:  2011-09-26       Impact factor: 12.701

2.  Glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) expression correlates with malignant choline phospholipid metabolite profiles in human breast cancer.

Authors:  Maria D Cao; Mailin Döpkens; Balaji Krishnamachary; Farhad Vesuna; Mayur M Gadiya; Per E Lønning; Zaver M Bhujwalla; Ingrid S Gribbestad; Kristine Glunde
Journal:  NMR Biomed       Date:  2012-01-26       Impact factor: 4.044

3.  Activation of phosphatidylcholine cycle enzymes in human epithelial ovarian cancer cells.

Authors:  Egidio Iorio; Alessandro Ricci; Marina Bagnoli; Maria Elena Pisanu; Giancarlo Castellano; Massimo Di Vito; Elisa Venturini; Kristine Glunde; Zaver M Bhujwalla; Delia Mezzanzanica; Silvana Canevari; Franca Podo
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

4.  Targeting choline phospholipid metabolism: GDPD5 and GDPD6 silencing decrease breast cancer cell proliferation, migration, and invasion.

Authors:  Maria Dung Cao; Menglin Cheng; Asif Rizwan; Lu Jiang; Balaji Krishnamachary; Zaver M Bhujwalla; Tone F Bathen; Kristine Glunde
Journal:  NMR Biomed       Date:  2016-06-30       Impact factor: 4.044

5.  Silencing of the glycerophosphocholine phosphodiesterase GDPD5 alters the phospholipid metabolite profile in a breast cancer model in vivo as monitored by (31) P MRS.

Authors:  J P Wijnen; L Jiang; T R Greenwood; M Cheng; M Döpkens; M D Cao; Z M Bhujwalla; B Krishnamachary; D W J Klomp; K Glunde
Journal:  NMR Biomed       Date:  2014-04-24       Impact factor: 4.044

6.  In vivo pH imaging with (99m)Tc-pHLIP.

Authors:  Sven Macholl; Matthew S Morrison; Peter Iveson; Bente E Arbo; Oleg A Andreev; Yana K Reshetnyak; Donald M Engelman; Edvin Johannesen
Journal:  Mol Imaging Biol       Date:  2012-12       Impact factor: 3.488

Review 7.  Magnetic resonance spectroscopy in metabolic and molecular imaging and diagnosis of cancer.

Authors:  Kristine Glunde; Dmitri Artemov; Marie-France Penet; Michael A Jacobs; Zaver M Bhujwalla
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

Review 8.  In vivo imaging of RNA interference.

Authors:  Hao Hong; Yin Zhang; Weibo Cai
Journal:  J Nucl Med       Date:  2010-01-15       Impact factor: 10.057

9.  Characterization of choline kinase in human endothelial cells.

Authors:  Noriko Mori; Mayur Gadiya; Flonné Wildes; Balaji Krishnamachary; Kristine Glunde; Zaver M Bhujwalla
Journal:  NMR Biomed       Date:  2013-06-18       Impact factor: 4.044

10.  Differential role of human choline kinase alpha and beta enzymes in lipid metabolism: implications in cancer onset and treatment.

Authors:  David Gallego-Ortega; Ana Ramirez de Molina; Maria Angeles Ramos; Fatima Valdes-Mora; Maria Gonzalez Barderas; Jacinto Sarmentero-Estrada; Juan Carlos Lacal
Journal:  PLoS One       Date:  2009-11-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.